Saito Hirokazu, Kadono Yoshihiro, Shono Takashi, Kamikawa Kentaro, Urata Atsushi, Nasu Jiro, Imamura Haruo, Matsushita Ikuo, Kakuma Tatsuyuki, Tada Shuji
Department of Gastroenterology, Kumamoto City Hospital, Kumamoto City 862-8505, Japan.
Department of Gastroenterology, Tsuruta Hospital, Kumamoto City 862-0925, Japan.
World J Gastrointest Endosc. 2022 Apr 16;14(4):215-225. doi: 10.4253/wjge.v14.i4.215.
As the aging population grows worldwide, the rates of endoscopic retrograde cholangiopancreatography (ERCP) for common bile duct stones (CBDS) in older patients with a poor performance status (PS) have been increasing. However, the data on the safety and efficacy of ERCP for CBDS in patients with a PS score of 3 or 4 are lacking, with only a few studies having investigated this issue among patients with poor PS.
To examine the safety and efficacy of ERCP for CBDS in patients with a PS score of 3 or 4.
This study utilized a retrospective multi-centered design of three institutions in Japan for 8 years to identify a total of 1343 patients with CBDS having native papillae who underwent therapeutic ERCP. As a result, 1113 patients with a PS 0-2 and 230 patients with a PS 3-4 were included. One-to-one propensity-score matching was performed to compare the safety and efficacy of ERCP for CBDS between patients with a PS 0-2 and those with a PS 3-4.
The overall ERCP-related complication rates in all patients and propensity score-matched patients with a PS 0-2 and 3-4 were 9.0% (100/1113) and 7.0% (16/230; = 0.37), and 4.6% (9/196) and 6.6% (13/196; = 0.51), respectively. In the propensity score-matched patients, complications were significantly more severe in the group with a PS 3-4 than in the group with a PS 0-2 group ( = 0.042). Risk factors for complications were indications of ERCP and absence of antibiotics in the multivariate analysis. Therapeutic success rates, including complete CBDS removal and permanent biliary stent placement, in propensity score-matched patients with a PS 0-2 and 3-4 were 97.4% (191/196) and 97.4% (191/196), respectively ( = 1.0).
ERCP for CBDS can be effectively performed in patients with a PS 3 or 4. Nevertheless, the indication for ERCP in such patients should be carefully considered with prophylactic antibiotics.
随着全球老龄化人口的增加,身体状况较差(PS)的老年患者因胆总管结石(CBDS)而行内镜逆行胰胆管造影术(ERCP)的比例一直在上升。然而,关于PS评分为3或4的患者行ERCP治疗CBDS的安全性和有效性的数据尚缺乏,仅有少数研究在PS较差的患者中探讨过这一问题。
探讨PS评分为3或4的患者行ERCP治疗CBDS的安全性和有效性。
本研究采用回顾性多中心设计,对日本3家机构8年间共1343例行治疗性ERCP的有天然乳头的CBDS患者进行分析。结果,纳入1113例PS为0 - 2的患者和230例PS为3 - 4的患者。进行一对一倾向评分匹配,以比较PS为0 - 2的患者和PS为3 - 4的患者行ERCP治疗CBDS的安全性和有效性。
所有患者以及倾向评分匹配的PS为0 - 2和3 - 4的患者中,ERCP相关的总体并发症发生率分别为9.0%(100/1113)和7.0%(16/230;P = 0.37),以及4.6%(9/196)和6.6%(13/196;P = 0.51)。在倾向评分匹配的患者中,PS为3 - 4的组并发症明显比PS为0 - 2的组更严重(P = 0.042)。多因素分析中,并发症的危险因素为ERCP的适应证和未使用抗生素。倾向评分匹配的PS为0 - 2和3 - 4的患者中,包括完全清除CBDS和放置永久性胆管支架的治疗成功率分别为97.4%(191/196)和97.4%(191/196)(P = 1.0)。
PS为3或4的患者可以有效地进行ERCP治疗CBDS。然而,对于此类患者行ERCP的适应证应结合预防性抗生素仔细考虑。